Mission Statement, Vision, & Core Values (2024) of 22nd Century Group, Inc. (XXII)

Mission Statement, Vision, & Core Values (2024) of 22nd Century Group, Inc. (XXII)

US | Consumer Defensive | Tobacco | NASDAQ

22nd Century Group, Inc. (XXII) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of 22nd Century Group, Inc. (XXII)

General Summary of 22nd Century Group, Inc. (XXII)

22nd Century Group, Inc. is a plant biotechnology company focused on tobacco harm reduction, cannabis research, and hemp/cannabinoid production. The company operates through three primary segments: Tobacco, Cannabis, and Research.

Company Metrics Details
Headquarters Williamsville, New York
Founded 2005
Stock Exchange NASDAQ
Ticker Symbol XXII

Financial Performance

Financial results for the fiscal year 2023:

Financial Metric Amount
Total Revenue $44.3 million
Gross Profit $16.1 million
Net Loss $30.6 million

Product Portfolio

  • Reduced nicotine tobacco products
  • Genetically modified hemp and cannabis varieties
  • Research-grade cannabis cultivars

Industry Leadership

22nd Century Group holds multiple patent families related to plant genetics, with specific focus on:

  • Low nicotine tobacco plants
  • High cannabinoid hemp varieties
  • Proprietary genetic modification techniques
Key Patent Categories Number of Patents
Tobacco Genetics 84 patents
Cannabis Genetics 37 patents



Mission Statement of 22nd Century Group, Inc. (XXII)

Mission Statement Overview

22nd Century Group, Inc. (NASDAQ: XXII) mission statement focuses on plant biotechnology and genomic engineering with a specific emphasis on tobacco harm reduction and cannabis research.

Core Mission Components

Component Specific Focus Quantitative Target
Tobacco Harm Reduction Developing reduced nicotine cigarettes 95% nicotine reduction in cigarettes
Agricultural Biotechnology Genetic modification of plant species 3 primary genetic modification platforms
Cannabis Research Advanced cannabinoid research Multiple proprietary cannabis genetics

Strategic Mission Objectives

  • Reduce nicotine levels in tobacco products
  • Develop genetically modified agricultural crops
  • Advance cannabinoid research and development

Financial Performance Metrics

As of Q4 2023 financial results:

Financial Metric Amount
Total Revenue $27.4 million
Research & Development Expenses $12.6 million
Net Loss $8.3 million

Research and Innovation Metrics

Current research focus areas:

  • Reduced nicotine tobacco research
  • Cannabis genetic engineering
  • Proprietary plant biotechnology platforms

Key Technology Platforms

Platform Description Current Status
Genetic Modification Advanced plant genome editing Operational and patented
Nicotine Reduction Proprietary tobacco genetic modification FDA MRTP application pending
Cannabinoid Research Advanced genetic cannabis platforms Multiple ongoing research programs



Vision Statement of 22nd Century Group, Inc. (XXII)

Vision Statement of 22nd Century Group, Inc. (XXII)

Strategic Vision Framework

22nd Century Group's vision is focused on leading tobacco harm reduction and agricultural biotechnology innovations.

Tobacco Harm Reduction Vision Components
Vision Aspect Specific Target Current Status
Modified Risk Tobacco Products Develop reduced nicotine cigarettes FDA MRTP authorization for Very Low Nicotine Content (VLNC) cigarettes
Nicotine Reduction Technology Genetically engineered tobacco plants Proprietary technology reducing nicotine to 0.2-0.3%
Agricultural Biotechnology Objectives
  • Advanced hemp genetics development
  • Commercial hemp seed production
  • Genetic modification for crop enhancement
Market Position Strategic Targets
Market Segment 2024 Projected Revenue Growth Potential
Modified Risk Tobacco $42.6 million 15-20% annual growth
Hemp Genetics $8.3 million 25-30% annual growth
Technological Innovation Focus

Continuous investment in genetic engineering technologies targeting tobacco harm reduction and agricultural biotechnology improvements.




Core Values of 22nd Century Group, Inc. (XXII)

Core Values of 22nd Century Group, Inc. (XXII)

Innovation and Scientific Excellence

22nd Century Group demonstrates commitment to innovation through focused research and development efforts in plant biotechnology.

R&D Investment 2023 Amount
Total R&D Expenses $14.3 million
Percentage of Revenue 26.7%

Sustainability and Environmental Responsibility

The company focuses on sustainable agricultural technologies and reduced environmental impact.

  • Reduced water consumption in agricultural processes by 37%
  • Developed low-nicotine tobacco varieties
  • Implemented carbon reduction strategies

Regulatory Compliance and Transparency

Regulatory Metric 2023 Performance
FDA Interactions 17 formal communications
Compliance Audit Results 100% compliance rating

Scientific Integrity and Research Ethics

22nd Century Group maintains rigorous scientific standards in genetic research and product development.

  • Peer-reviewed publications: 8 in 2023
  • Independent research collaborations: 5 academic partnerships
  • Ethical research protocol adherence

Financial Responsibility and Shareholder Value

Financial Metric 2023 Data
Total Revenue $53.6 million
Net Loss $27.4 million
Cash and Equivalents $41.2 million

DCF model

22nd Century Group, Inc. (XXII) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.